Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing antibodies (NAbs) lack cross-reactivity between SARS-CoV species and variants and fail to mediate long-term protection against infection. The maintained protection against severe disease and death by vaccination suggests a role for cross-reactive T cells. We generated vaccines containing sequences from the spike or receptor binding domain, the membrane and/or nucleoprotein that induced only T cells, or T cells and NAbs, to understand their individual roles. In three models with homologous or heterologous challenge, high levels of vaccine-induced SARS-CoV-2 NAbs protected against neither infection nor mild histological disease but conferred rapid viral control limiting the histological damage. With no or low levels of NAbs, vaccine-primed T cells, in mice mainly CD8+ T cells, partially controlled viral replication and promoted NAb recall responses. T cells failed to protect against histological damage, presumably because of viral spread and subsequent T cell-mediated killing. Neither vaccine- nor infection-induced NAbs seem to provide long-lasting protective immunity against SARS-CoV-2. Thus, a more realistic approach for universal SARS-CoV-2 vaccines should be to aim for broadly cross-reactive NAbs in combination with long-lasting highly cross-reactive T cells. Long-lived cross-reactive T cells are likely key to prevent severe disease and fatalities during current and future pandemics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Molecular therapy : the journal of the American Society of Gene Therapy - 32(2024), 2 vom: 07. Feb., Seite 540-555 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan, Jingyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 15.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ymthe.2024.01.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367035839 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367035839 | ||
| 003 | DE-627 | ||
| 005 | 20240215232011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymthe.2024.01.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM367035839 | ||
| 035 | |a (NLM)38213030 | ||
| 035 | |a (PII)S1525-0016(24)00007-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yan, Jingyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing antibodies (NAbs) lack cross-reactivity between SARS-CoV species and variants and fail to mediate long-term protection against infection. The maintained protection against severe disease and death by vaccination suggests a role for cross-reactive T cells. We generated vaccines containing sequences from the spike or receptor binding domain, the membrane and/or nucleoprotein that induced only T cells, or T cells and NAbs, to understand their individual roles. In three models with homologous or heterologous challenge, high levels of vaccine-induced SARS-CoV-2 NAbs protected against neither infection nor mild histological disease but conferred rapid viral control limiting the histological damage. With no or low levels of NAbs, vaccine-primed T cells, in mice mainly CD8+ T cells, partially controlled viral replication and promoted NAb recall responses. T cells failed to protect against histological damage, presumably because of viral spread and subsequent T cell-mediated killing. Neither vaccine- nor infection-induced NAbs seem to provide long-lasting protective immunity against SARS-CoV-2. Thus, a more realistic approach for universal SARS-CoV-2 vaccines should be to aim for broadly cross-reactive NAbs in combination with long-lasting highly cross-reactive T cells. Long-lived cross-reactive T cells are likely key to prevent severe disease and fatalities during current and future pandemics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD8(+) | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a DNA vaccine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a challenge models | |
| 650 | 4 | |a in vivo electroporation | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Bangalore, Chandrashekar Ravenna |e verfasserin |4 aut | |
| 700 | 1 | |a Nikouyan, Negin |e verfasserin |4 aut | |
| 700 | 1 | |a Appelberg, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Daniela Nacimento |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Haidong |e verfasserin |4 aut | |
| 700 | 1 | |a Pasetto, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Friedemann |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Sofie |e verfasserin |4 aut | |
| 700 | 1 | |a Larsson, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Höglund, Urban |e verfasserin |4 aut | |
| 700 | 1 | |a Bogdanovic, Gordana |e verfasserin |4 aut | |
| 700 | 1 | |a Grabbe, Malin |e verfasserin |4 aut | |
| 700 | 1 | |a Aleman, Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Szekely, Laszlo |e verfasserin |4 aut | |
| 700 | 1 | |a Szakos, Attila |e verfasserin |4 aut | |
| 700 | 1 | |a Tuvesson, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Gidlund, Eva-Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Cadossi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Salati, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Tegel, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Hober, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Frelin, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Mirazimi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ahlén, Gustaf |e verfasserin |4 aut | |
| 700 | 1 | |a Sällberg, Matti |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy : the journal of the American Society of Gene Therapy |d 2000 |g 32(2024), 2 vom: 07. Feb., Seite 540-555 |w (DE-627)NLM108239381 |x 1525-0024 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:2 |g day:07 |g month:02 |g pages:540-555 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymthe.2024.01.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 2 |b 07 |c 02 |h 540-555 | ||